SURF Stock Price
SURF RSI Chart
SURF Valuation
SURF Price/Sales (Trailing)
SURF Profitability
SURF Fundamentals
SURF Revenue
SURF Earnings
Price Action
Last 7 days
12.5%
Last 30 days
21.5%
Last 90 days
41.0%
Trailing 12 Months
-16.9%
SURF Financial Health
SURF Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SURF
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-08 | GRAYZEL DAVID S. | back to issuer | - | - | -2,945,450 | - |
2023-09-08 | ROSS ROBERT W. | back to issuer | - | - | -83,193 | chief executive officer |
2023-09-08 | ONEILL ALISON | back to issuer | - | - | -56,686 | chief medical officer |
2023-09-08 | Goater Jeff | back to issuer | - | - | -129,222 | - |
2023-09-08 | FEES JESSICA | back to issuer | - | - | -101,915 | chief financial officer |
2023-09-08 | RATH HENRY C. | back to issuer | - | - | -44,971 | chief business officer |
2023-09-08 | Adams Chandra | back to issuer | - | - | -23,884 | deputy gc |
2023-09-08 | Palombella Vito J. | back to issuer | - | - | -87,212 | chief scientific officer |
2023-09-08 | Sigal Charles Elliott | back to issuer | - | - | -45,453 | - |
2023-08-01 | Adams Chandra | sold | -3,666 | 0.94 | -3,901 | deputy gc |
Which funds bought or sold SURF recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | sold off | -100 | -20,000 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | unchanged | - | 1,816 | 9,104 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 1.85 | 162 | 765 | -% |
2023-08-15 | Cornerstone Planning Group LLC | new | - | 217 | 217 | -% |
2023-08-15 | Formidable Asset Management, LLC | unchanged | - | 2,000 | 13,000 | -% |
2023-08-15 | Ground Swell Capital, LLC | new | - | 17,662 | 17,662 | 0.02% |
2023-08-15 | GOLDMAN SACHS GROUP INC | sold off | -100 | -442,738 | - | -% |
2023-08-14 | MACQUARIE GROUP LTD | unchanged | - | 59,000 | 304,000 | -% |
2023-08-14 | FEDERATED HERMES, INC. | unchanged | - | 451 | 2,294 | -% |
2023-08-14 | TWO SIGMA ADVISERS, LP | reduced | -25.57 | -1,795 | 22,523 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Surface Oncology
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 20, 2023 | adar1 partners, lp | 5.24% | 3,183,242 | SC 13G | |
| Feb 13, 2023 | ecor1 capital, llc | 6.5% | 3,924,713 | SC 13G/A | |
| Jan 31, 2023 | atlas venture fund ix, l.p. | 4.87% | 2,945,453 | SC 13G/A | |
| May 09, 2022 | blackrock inc. | 4.6% | 2,502,271 | SC 13G | |
| Mar 14, 2022 | ecor1 capital, llc | 9.9% | 4,653,000 | SC 13G | |
| Feb 10, 2022 | eli lilly & co | 3.5% | 1,593,997 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 11.54% | 5,326,127 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 04, 2022 | blackrock inc. | 5.6% | 2,562,685 | SC 13G | |
| Jan 25, 2022 | atlas venture fund ix, l.p. | 6.38% | 2,945,453 | SC 13G/A |
Recent SEC filings of Surface Oncology
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 15-12G | 15-12G | |
| Sep 12, 2023 | EFFECT | EFFECT | |
| Sep 12, 2023 | EFFECT | EFFECT | |
| Sep 08, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 08, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 08, 2023 | S-8 POS | Employee Benefits Plan | |
| Sep 08, 2023 | POS AM | POS AM | |
| Sep 08, 2023 | POS AM | POS AM | |
| Sep 08, 2023 | 8-K | Current Report | |
| Sep 08, 2023 | 4 | Insider Trading |
Peers (Alternatives to Surface Oncology)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 143.9B | 26.6B | 4.94% | 20.46% | 18.04 | 5.41 | 0.75% | 21.34% |
GILD | 94.2B | 27.4B | -1.73% | 23.33% | 17.17 | 3.44 | -0.48% | 32.56% |
MRNA | 37.4B | 10.7B | -12.34% | -18.02% | 30.97 | 3.51 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -2.41% | 31.83% | 14.01 | 3.74 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 6.64% | 14.01% | 63.44 | 6.69 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -10.44% | 191.13% | -7.34 | 48.33 | 54.84% | -12.96% |
DNLI | 2.9B | - | -7.08% | -17.64% | -22.89 | 37.44 | 122.90% | 54.78% |
BEAM | 1.8B | 80.2M | 1.68% | -49.31% | -5.62 | 22.95 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.4B | 121.2M | -15.01% | -21.70% | -4.98 | 11.8 | -70.36% | -531.73% |
REPL | 941.3M | 15.3M | -22.34% | -0.87% | -5.18 | 61.48 | 1090.59% | -36.57% |
NVAX | 670.5M | 1.6B | -11.68% | -62.32% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 199.0M | - | -23.19% | -90.40% | -0.94 | 1.45 | 116.83% | 16.61% |
SGMO | 118.0M | - | -12.12% | -85.84% | -0.59 | 0.49 | 113.96% | -15.19% |
VXRT | 107.9M | 2.1M | -9.82% | -66.03% | -1.07 | 52.51 | 487.70% | -8.66% |
IBIO | 3.7M | - | -11.16% | -96.28% | -0.05 | 3.21 | - | -129.46% |
Surface Oncology News
Returns for SURF
Cumulative Returns on SURF
-35.5%
5-Year Cumulative Returns
-46.7%
3-Year Cumulative Returns
Risks for SURF
What is the probability of a big loss on SURF?
100%
Probability that Surface Oncology stock will be more than 20% underwater in next one year
100%
Probability that Surface Oncology stock will be more than 30% underwater in next one year.
100%
Probability that Surface Oncology stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SURF drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Surface Oncology was unfortunately bought at previous high price.
Drawdowns
Financials for Surface Oncology
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Revenue | -100.0% | - | 30,000,000 | 23,171,750 | 16,343,500 | 9,515,250 | 2,687,000 | 33,555,750 | 64,424,500 | 95,293,250 | 126,162,000 | - | - | - | - | - | - | - | - | - | - | 56,649,000 |
| Operating Expenses | -2.7% | 89,386,000 | 91,869,000 | 94,213,000 | 91,199,000 | 85,678,000 | 78,700,000 | 74,772,000 | 69,246,000 | 64,686,000 | 64,576,000 | 61,747,000 | 65,289,000 | 69,399,000 | 72,726,000 | 71,300,000 | 73,160,000 | 73,518,000 | 68,568,000 | 72,337,000 | 69,329,000 | 63,042,000 |
| S&GA Expenses | 6.0% | 26,362,000 | 24,866,000 | 26,175,000 | 26,018,000 | 26,026,000 | 25,128,000 | 26,794,000 | 25,851,000 | 24,412,000 | 23,558,000 | 19,800,000 | 19,880,000 | 20,302,000 | 20,608,000 | 20,318,000 | 19,311,000 | 17,807,000 | 16,076,000 | 14,084,000 | 14,758,000 | 12,849,000 |
| R&D Expenses | -10.8% | 59,790,000 | 67,003,000 | 68,038,000 | 65,181,000 | 59,652,000 | 53,572,000 | 47,978,000 | 43,395,000 | 40,274,000 | 41,018,000 | 41,947,000 | 45,409,000 | 49,097,000 | 52,118,000 | 50,982,000 | 53,849,000 | 55,711,000 | 52,492,000 | 58,253,000 | 54,571,000 | 50,193,000 |
| EBITDA | - | - | - | - | -74,506,000 | -74,773,000 | -74,370,000 | - | - | 62,700,000 | 62,068,000 | -50,832,000 | -52,256,000 | -52,523,666 | -53,004,000 | -4,908,000 | -5,027,000 | -5,141,000 | - | - | - | - |
| EBITDA Margin | - | - | - | - | -27.73 | -27.83 | -27.68 | - | - | 0.50 | 0.49 | -0.90 | -0.92 | -0.93 | -0.94 | -0.09 | -0.09 | -0.09 | - | - | - | - |
| Interest Expenses | 83.4% | 5,771,000 | 3,146,000 | 2,929,000 | 2,521,000 | 2,204,000 | 2,546,000 | 2,479,000 | 3,527,000 | 3,538,000 | 2,855,000 | 2,381,000 | 912,000 | 646,667 | 145,000 | - | - | - | - | - | - | - |
| Earnings Before Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2,482,666 | 1,728,000 | 14,318,667 |
| EBT Margin | - | - | - | - | -29.21 | -29.21 | -29.21 | - | - | 0.47 | 0.47 | -0.97 | -0.97 | -0.97 | -0.97 | -0.12 | -0.12 | -0.12 | - | - | - | - |
| Net Income | -45.5% | -92,505,000 | -63,586,000 | -66,304,000 | -62,957,000 | -56,725,000 | -78,485,000 | 12,913,000 | 17,032,000 | 21,206,000 | 59,337,000 | -23,965,000 | -25,069,000 | -28,020,000 | -54,789,000 | -43,570,000 | -43,914,000 | -42,008,000 | -6,597,000 | -17,635,000 | -14,818,000 | -5,539,000 |
| Net Income Margin | 100.0% | - | -2.12 | -2.20 | -23.43 | -21.11 | -29.21 | 0.38 | 0.26 | 0.17 | 0.47 | -0.42 | -0.44 | -0.49 | - | - | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -60,049,000 | -53,928,000 | -50,352,000 | -67,102,000 | -62,464,000 | 25,749,000 | 30,796,000 | 26,590,000 | 29,954,000 | -55,803,000 | -60,203,000 | -58,093,000 | -61,678,000 | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -51.8% | 66.00 | 137 | 160 | 182 | 194 | 218 | 191 | 189 | 206 | 215 | 217 | 145 | 155 | 131 | 132 | 139 | 155 | 171 | 174 | 186 | 202 |
| Current Assets | -43.5% | 61.00 | 107 | 129 | 150 | 162 | 184 | 157 | 155 | 171 | 179 | 181 | 108 | 118 | 93.00 | 108 | 114 | 130 | 145 | 165 | 178 | 194 |
| Cash Equivalents | -48.8% | 15.00 | 29.00 | 51.00 | 65.00 | 75.00 | 66.00 | 56.00 | 61.00 | 83.00 | 101 | 175 | 99.00 | 93.00 | 56.00 | 47.00 | 39.00 | 38.00 | 41.00 | 83.00 | 42.00 | 51.00 |
| Net PPE | -44.6% | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 6.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 |
| Liabilities | -72.5% | 17.00 | 61.00 | 67.00 | 69.00 | 68.00 | 71.00 | 72.00 | 57.00 | 57.00 | 56.00 | 61.00 | 59.00 | 57.00 | 50.00 | 75.00 | 70.00 | 71.00 | 70.00 | 71.00 | 80.00 | 80.00 |
| Current Liabilities | 14.1% | 17.00 | 15.00 | 16.00 | 18.00 | 20.00 | 20.00 | 20.00 | 16.00 | 19.00 | 15.00 | 18.00 | 14.00 | 11.00 | 13.00 | 19.00 | 16.00 | 15.00 | 13.00 | 27.00 | 28.00 | 25.00 |
| Shareholder's Equity | -35.1% | 49.00 | 76.00 | 93.00 | 113 | 126 | 147 | 119 | 131 | 148 | 159 | 156 | 86.00 | 98.00 | 82.00 | 57.00 | 69.00 | 84.00 | 100 | 103 | 106 | 122 |
| Retained Earnings | -12.6% | -252 | -224 | -204 | -183 | -159 | -134 | -140 | -116 | -96.80 | -77.82 | -62.26 | -129 | -113 | -99.02 | -121 | -105 | -88.76 | -71.00 | -66.81 | -62.07 | -44.85 |
| Additional Paid-In Capital | 0.4% | 302 | 300 | 299 | 297 | 287 | 282 | 260 | 248 | 245 | 237 | 218 | 216 | 211 | 180 | 178 | 174 | 173 | 171 | 170 | 168 | 167 |
| Shares Outstanding | 0.0% | 61.00 | 61.00 | 61.00 | 61.00 | 55.00 | 49.00 | 47.00 | 45.00 | 44.00 | 42.00 | 41.00 | 40.00 | 33.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 17.00 | 22.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -40.6% | -83,581 | -59,425 | -59,552 | -53,655 | -50,086 | -66,947 | -62,344 | 25,822 | 30,816 | 26,610 | 29,997 | -55,650 | -59,779 | -57,408 | -60,140 | -60,744 | -58,497 | -62,541 | -13,222 | -13,746 | -11,064 |
| Share Based Compensation | -12.7% | 6,117 | 7,004 | 7,223 | 7,547 | 7,825 | 8,031 | 8,546 | 8,655 | 8,574 | 8,295 | 7,765 | 7,358 | 6,961 | 6,446 | 5,991 | 5,668 | 5,316 | 5,321 | 5,217 | 4,668 | 6,258 |
| Cashflow From Investing | 252.7% | 41,353 | 11,726 | 22,757 | 5,471 | -3,032 | -16,153 | -99,252 | -86,512 | -61,981 | -37,154 | 58,307 | 70,135 | 68,938 | 65,294 | 16,965 | 57,136 | 44,931 | -65,806 | -36,584 | -85,139 | -85,846 |
| Cashflow From Financing | -275.5% | -19,349 | 11,024 | 31,660 | 52,432 | 44,607 | 48,231 | 42,500 | 22,072 | 21,375 | 54,651 | 40,082 | 46,855 | 46,612 | 7,617 | 7,415 | 539 | 552 | 110,485 | 110,376 | 109,270 | 109,031 |
SURF Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Statement of Comprehensive Income [Abstract] | ||||
| License-related revenue | $ 0 | $ 0 | $ 0 | $ 30,000 |
| Operating expenses: | ||||
| Research and development | 13,831 | 18,198 | 27,608 | 34,822 |
| General and administrative | 8,576 | 6,426 | 14,460 | 12,967 |
| Restructuring charges | 3,234 | 0 | 3,234 | 0 |
| Total operating expenses | 25,641 | 24,624 | 45,302 | 47,789 |
| Loss from operations | (25,641) | (24,624) | (45,302) | (17,789) |
| Interest expense | (3,108) | (733) | (4,040) | (1,415) |
| Other income (expense), net | 557 | 144 | 1,409 | 190 |
| Net loss | $ (28,192) | $ (25,213) | $ (47,933) | $ (19,014) |
| Net loss per share — basic (in dollars per share) | $ (0.46) | $ (0.46) | $ (0.79) | $ (0.37) |
| Net loss per share — diluted (in dollars per share) | $ (0.46) | $ (0.46) | $ (0.79) | $ (0.37) |
| Weighted average common shares outstanding— basic (in shares) | 60,717,899 | 54,654,822 | 60,673,195 | 51,647,148 |
| Weighted average common shares outstanding— diluted (in shares) | 60,717,899 | 54,654,822 | 60,673,195 | 51,647,148 |
| Comprehensive loss: | ||||
| Net loss | $ (28,192) | $ (25,213) | $ (47,933) | $ (19,014) |
| Other comprehensive loss: | ||||
| Unrealized gain (loss) on marketable securities, net of tax of $0 | 348 | (259) | 794 | (949) |
| Comprehensive loss | $ (27,844) | $ (25,472) | $ (47,139) | $ (19,963) |
SURF Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 14,842 | $ 50,910 |
| Marketable securities | 41,416 | 73,913 |
| Prepaid expenses and other current assets | 4,330 | 4,317 |
| Total current assets | 60,588 | 129,140 |
| Property and equipment, net | 2,499 | 4,866 |
| Operating lease right-of-use asset | 2,919 | 24,307 |
| Restricted cash | 0 | 1,595 |
| Other assets | 0 | 2 |
| Total assets | 66,006 | 159,910 |
| Current liabilities: | ||
| Accounts payable | 609 | 256 |
| Accrued expenses and other current liabilities | 6,731 | 10,214 |
| Operating lease liability | 9,488 | 5,790 |
| Total current liabilities | 16,828 | 16,260 |
| Operating lease liability, non-current | 0 | 24,662 |
| Convertible note payable, non-current | 0 | 25,585 |
| Total liabilities | 16,828 | 66,507 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 60,730,274 and 60,578,956 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 6 | 6 |
| Additional paid-in capital | 301,655 | 298,741 |
| Accumulated other comprehensive loss | (221) | (1,015) |
| Accumulated deficit | (252,262) | (204,329) |
| Total stockholders’ equity | 49,178 | 93,403 |
| Total liabilities and stockholders’ equity | $ 66,006 | $ 159,910 |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.